MAI Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

MAI Capital Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.9K	Hold	125	–	–	﹤0.01%	3179
2025 Q4	$10.3K	Hold	125	–	–	﹤0.01%	2834
2025 Q3	$8.73K	Hold	125	–	–	﹤0.01%	2802
2025 Q2	$8.01K	Hold	125	–	–	﹤0.01%	2846
2025 Q1	$7.93K	Hold	125	–	–	﹤0.01%	2576
2024 Q4	$8.32K	Buy	+125	New	+$8.62K	﹤0.01%	2595

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

MAI Capital Management's PBE Position: Q1 2026 in Review

MAI Capital Management held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q1 2026 at 125 shares worth $9.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3179.

MAI Capital Management first reported a position in PBE in Q4 2024 and has held it in 6 quarters since. The position peaked at $10.3K in Q4 2025. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

MAI Capital Management held 125 shares of Invesco Biotechnology & Genome ETF worth $9.9K as of Q1 2026.
MAI Capital Management left its Invesco Biotechnology & Genome ETF share count unchanged in Q1 2026.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3179 holding.
MAI Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q4 2024 and has held it in 6 quarters since.
MAI Capital Management's Invesco Biotechnology & Genome ETF position peaked at $10.3K in Q4 2025.
100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.